NTRK1 and colorectal carcinoma: Secondly, the enrichment of response to multiple kinase inhibitors in the NTRK1/2/3-high subsets of CRC may indicate that NTRK1/2/3 overexpression can be a predictive biomarker for these kinase inhibitors.